avec le lancement prévu ce trimestre d'une ph3 pour un composé naproxene/esomeprazole à 400 mg en partenariat avec pozen!
The PN 200 pilot Phase III study is ahead of schedule and fully enrolled. POZEN is on schedule to commence the Phase III trials for PN 400 (naproxen/esomeprazole combination) during the third quarter of 2007, pending results of the above mentioned pilot study." - Pozen Website March 07, 2007
" If we and AstraZeneca are satisfied that the PN 200 trial will be successful based on our assessment of the preliminary data, and we have successfully completed a cross-over gastric pH-based dose ranging study for PN 400 to be initiated in the second quarter of 2007, we will begin our Phase 3 program for PN 400 as soon as clinical trial material is manufactured and ready for use." - Pozen Form 10Q May 03, 2007.
Malgré tout la population visée n'est pas la même(hypertendus), et on a un peu d'avance!
tiens, et astra anticiperait-elle sur les nostatines?
3. AstraZeneca, Abbott plan combo pill
Comment | Forward to a friend
Abbott and AstraZeneca are planning to Phase III trial a pill combining two drugs to target all three major blood lipids--LDL-C "bad" cholesterol, HDL-C "good" cholesterol, and triglycerides. Abbott's ABT-335 and AstraZeneca's Crestor will make up the combo drug. If the drug is successful in trials, the companies plan to market the drug by 2009. Programs combining drugs have become very popular as of late as they offer beleaguered drug developers a way to make a quick buck.